InflaRx (IFRX) Set to Post Earnings on Tuesday

InflaRx (NASDAQ:IFRX) is anticipated to announce its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.07) per share and revenue of $0.01 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 9:30 AM ET.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). On average, analysts expect InflaRx to post ($0.31) EPS for the current fiscal year and ($0.38) EPS for the next fiscal year.

InflaRx Price Performance

NASDAQ:IFRX opened at $1.66 on Monday. The firm has a market cap of $244.63 million, a PE ratio of -2.86 and a beta of 2.38. The firm has a 50 day simple moving average of $1.87 and a 200-day simple moving average of $1.63. InflaRx has a 1-year low of $0.80 and a 1-year high of $2.95.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on IFRX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research report on Monday, September 21st. Cantor Fitzgerald raised their target price on InflaRx from $4.00 to $6.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Needham & Company LLC began coverage on InflaRx in a research note on Monday, September 14th. They issued a “buy” rating and a $8.00 price target on the stock. Finally, Zacks Research downgraded InflaRx from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.43.

About InflaRx

InflaRx N.V. (NASDAQ: IFRX) is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Founded in 2007 and headquartered in Jena, Germany, the company’s research is centered on the complement system, an important part of the immune response. InflaRx seeks to selectively block complement component C5a, a potent inflammatory mediator, while preserving other aspects of immune-system function.

The company’s lead product, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a.